Evidence map›Paper›PMID 35437713›Full record

ReviewHeart failure reviews2022

Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.

Filippos Triposkiadis, Andrew Xanthopoulos, John Skoularigis, Randall C Starling

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Vericiguat: A New Horizon for Heart Failure Treatment.Reviews in cardiovascular medicine · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Filippos TriposkiadisDepartment of Cardiology, University Hospital of Larissa, PO Box 1425, 411 10, Larissa, Greece. ftriposkiadis@gmail.com.ORCID 0000-0001-6433-4016
Andrew XanthopoulosDepartment of Cardiology, University Hospital of Larissa, PO Box 1425, 411 10, Larissa, Greece.
John SkoularigisDepartment of Cardiology, University Hospital of Larissa, PO Box 1425, 411 10, Larissa, Greece.
Randall C StarlingKaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular, and Thoracic Institute, Cleveland, OH, USA.
University Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nitric oxide (NO)-guanylate cyclase (GC)-cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal function. Phosphodiesterase-5 inhibitors (PDE-5i) inhibit cGMP degradation, whereas both soluble guanylate cyclase (sGC) stimulators and sGC activators directly increase sGC. PDE-5i (e.g. sildenafil, tadalafil) and sGC stimulators (e.g. riociguat, vericiguat) have been extensively used in pulmonary artery hypertension (PAH) and heart failure (HF). PDE-5i have also been used in end-stage HF before and after left ventricular (LV) assist device (LVAD) implantation. Augmentation of NO-GC-cGMP signalling with PDE-5i causes selective pulmonary vasodilation, which is highly effective in PAH but may have controversial, potentially adverse effects in HF, including pre-LVAD implant due to device unmasking of PDE-5i-induced RV dysfunction. In contrast, retrospective analyses have demonstrated that PDE-5i have beneficial effects when initiated post LVAD implant due to the improved haemodynamics of the supported LV and the pleiotropic actions of these compounds. sGC stimulators, in turn, are effective both in PAH and in HF due to their balanced pulmonary and systemic vasodilation, and as such they are preferable to PDE-5i if the use of a pulmonary vasodilator is needed in HF patients, including those listed for LVAD implantation. Regarding the effectiveness of PDE-5i and sGC stimulators when initiated post LVAD implant, these two groups of compounds should be tested in a randomized control trial.

Indexed as

Heart FailurePulmonary Arterial HypertensionCyclic GMPCyclic Nucleotide Phosphodiesterases, Type 5Guanosine MonophosphateGuanylate CyclaseHumansNitric OxidePhosphodiesterase 5 InhibitorsRetrospective StudiesSildenafil CitrateSoluble Guanylyl CyclaseTadalafilVasodilator AgentsCyclic GMPCyclic Nucleotide Phosphodiesterases, Type 5Guanosine MonophosphateGuanylate CyclaseNitric OxidePhosphodiesterase 5 InhibitorsSildenafil CitrateSoluble Guanylyl CyclaseTadalafilVasodilator AgentsHeart failureLeft ventricular assist deviceNitric oxidePhosphodiesterase-5 inhibitorsPulmonary hypertensionSoluble guanylate cyclase

Identifiers

PMID35437713
OpenAlexW4224256653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.